JSI RESOURCES: Publications

Advancing PrEP


JSI applies research, provides technical support, and supports policy advancement to increase PrEP access globally. PrEP, short for pre-exposure prophylaxis, is a daily dose of antiretroviral medication that can reduce HIV acquisition risk by 92% to 99% for HIV-negative individuals. At the request of governments, public health agencies, and community health stakeholders, JSI works to expand and scale-up PrEP usage while dispelling stigma and misinformation.

Partner with Us

We strive to build lasting relationships to produce better health outcomes for all.